Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: Medical, ethical, and financial implications

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 6, 2013, Pages 661-663

  Dreyfuss, Didier ^a,b   Ricard, Jean Damien ^a,b   Gaudry, Stéphane ^a,b  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

CANDIDEMIA; DRUG EFFICACY; DRUG FATALITY; FUNDING; HUMAN; HYDRATION; INVASIVE CANDIDIASIS; LETTER; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CREATININE; CRITICAL ILLNESS; CROSS INFECTION; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; PHYSICIAN'S PRACTICE PATTERNS; RENAL INSUFFICIENCY;

EID: 84875171555     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.187.6.661     Document Type: Letter

References (23)

1. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111.
2. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-672.
3. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment. Intensive Care Med 2009;35:206-214.
4. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
5. Branch RA. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988;148: 2389-2394.
6. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-388.
7. Oto OA, Paydas S, Disel U, Yavuz S, Seydaoglu G. Amphotericin B deoxycholate (d-amb) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses 2007;50:135-139.
8. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-582.
9. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004;54:803-808.
10. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
11. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771.
12. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442.
13. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54:1110-1122.
14. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl JMed 2007;356:2472-2482.
15. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535.
16. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, Davies SF, Dismukes WE, Hage CA, Marr KA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011;183:96-128.
17. Emanuel EJ, Thompson DF. The concept of conflicts of interest. In: Emanuel EJ, Grady C, Crouch RA, Lie RK, Miller FG, Wendler D, editors. The Oxford textbook of clinical research ethics. New York: Oxford University Press; 2008. pp. 758-766.
18. Hampson LA, Bekelman JE, Gross CP. Empirical data on conflicts of interest. In: Emanuel EJ, Grady C, Crouch RA, Lie RK, Miller FG, Wendler D, editors. The Oxford textbook of clinical research ethics. New York: Oxford University Press; 2008. pp. 767-779.
19. Angell M. Industry-sponsored clinical research: a broken system. JAMA 2008;300:1069-1071.
20. Weinberger SE. Providing high-value, cost-conscious care: a critical seventh general competency for physicians. Ann Intern Med 2011;155:386-388.
21. Rosenbaum L, Lamas D. Cents and sensitivity: teaching physicians to think about costs. N Engl J Med 2012;367:99-101.
22. Horwitz E, Shavit O, Shouval R, Hoffman A, Shapiro M, Moses AE. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. Int J Clin Pharm 2012.
23. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36:943-951.